Alkem Laboratories has officially announced the launch of A to Z Daily, a comprehensive multivitamin supplement designed to provide holistic nutritional support for both body and mind. The company made this announcement through a press release filed under Regulation 30 with stock exchanges.

Product Specifications and Formulation

A to Z Daily represents a significant advancement in multivitamin supplementation, featuring a carefully crafted formulation of 26 essential vitamins, minerals, and select botanicals. The product is specifically designed for adults seeking everyday nutritional support beyond conventional multivitamins.

Key Nutritional Components

The supplement incorporates essential vitamins and minerals including Vitamin B complex, Vitamin D3, Vitamin C, Zinc, and Iron, specifically chosen for their roles in boosting energy levels, reducing fatigue, and improving immunity. Additionally, the formulation includes clinically-researched botanicals such as Ashwagandha, Bacopa monnieri (Brahmi), Panax ginseng, and the amino acid L-theanine.

Strategic Market Positioning

Dr. Vikas Gupta, Chief Executive Officer of Alkem, emphasized the product's unique positioning in addressing modern lifestyle challenges. "Our current lifestyles are placing sustained demands not just on physical health but also on mental well-being. A to Z Daily brings together essential ingredients to provide a balanced, everyday support for both body and mind. It is positioned not as a quick fix, but as a consistent, long-term approach for people seeking to manage everyday stress while improving overall vitality."

Unlike conventional multivitamins that primarily address nutritional deficiencies, A to Z Daily is designed as an everyday support supplement for maintaining physical energy while helping individuals stay mentally composed through daily pressures and routines. The product is intended for consistent, long-term use as part of a preventive wellness approach.

Company Profile and Market Presence

Alkem Laboratories Ltd. operates as the sixth largest pharmaceutical company in the Indian market, with dominant positions in anti-infectives, gastrointestinal, pain management drugs and supplements. The company maintains 18 state-of-the-art manufacturing facilities and research centers across India and the US, with meaningful presence in the US, Latin America, Australia and several Asian countries.

Alkem Laboratories has officially confirmed a substantial increase in its planned investment for a new greenfield formulations manufacturing plant in Ujjain, Madhya Pradesh. The pharmaceutical company's board approved the enhanced capital allocation on April 2, 2026, nearly doubling the original investment commitment as disclosed under Regulation 30 of SEBI LODR Regulations.

Investment Enhancement Details

The board's decision represents a significant scaling up of the company's manufacturing expansion plans. The revised investment framework demonstrates Alkem Laboratories' confidence in the project's potential and its commitment to strengthening production capabilities.

Strategic Manufacturing Expansion

The greenfield facility in Ujjain represents a strategic addition to Alkem Laboratories' manufacturing network. The formulations plant will enhance the company's production capacity and operational flexibility in the pharmaceutical sector. The company had earlier received an allotment letter dated March 18, 2026, from DMIC Vikram Udyogpuri Limited for the 30-acre land parcel.

Regulatory Compliance and Timeline

The investment approval follows proper regulatory disclosure protocols under SEBI LODR Regulations. The board had initially approved an investment of up to ₹533 crores in March 2026, which has now been enhanced to ₹1,036 crores. The phased implementation approach allows for controlled deployment of capital and systematic facility development.

The enhanced investment commitment reflects Alkem Laboratories' strategic focus on expanding its manufacturing infrastructure and strengthening its position in the pharmaceutical formulations market.